Gilead Signs an Agreement with Carna Biosciences to Develop and Commercialize Immuno-Oncology Therapies
Shots:
- Carna to receive $20M upfront- up to $450M as development & commercial milestones and royalties on sales. Gilead to get WW rights to develop and commercialize inhibitors against immuno-oncology target and an exclusive right to access Carna’s lipid kinase drug discovery platform
- The focus of the collaboration is to advance novel immunotherapies targeting cancer by utilizing Carna’s lipid kinase drug discovery platform
- Carna Biosciences focuses on developing kinase inhibitors targeting oncology- autoimmune and neurological diseases by inhibiting kinases which are important drivers for the diseases
Click here to read full press release/ article
Ref: Gilead | Image: Gilead
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com